CRVS Corvus Pharmaceuticals

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2025 Jefferies Global Healthcare Conference, which is being held in New York, NY. The presentation will be on Thursday, June 5 from 9:20-9:50 am ET.

A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the section of the Corvus website.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit  or follow the Company on .

INVESTOR CONTACT:

Leiv Lea

Chief Financial Officer

Corvus Pharmaceuticals, Inc.



MEDIA CONTACT:

Sheryl Seapy

Real Chemistry





EN
28/05/2025

Underlying

CRVSCorvus Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Corvus Pharmaceuticals

 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthc...

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2025 Jefferies Global Healthcare Conference, which is being held in New York, NY. The presentation will be on Thursday, June 5 from 9:20-9:50 am ET. A webcast of the presentation will be available live and for 90 days ...

May 28, 2025 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals Provides Business Update and Reports First Quar...

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open Early exercise of common stock warrants by stockholders providing cash proceeds of approximately $31.3 million Soquelitinib data to be highlighted on confere...

May 8, 2025 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Cont...

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting Company to discuss data today on its first quarter 2025 business update conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus...

May 8, 2025 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Contro...

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025 SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical com...

April 23, 2025 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of D...

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company’s board of directors. Mr. van den Broek has more than 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst and board member. “We’re thrilled to welcome Richard to our board,” said Richard A. Mill...

April 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch